Finch Therapeutics and Takeda Announce Global Collaboration to Develop Microbiome Therapeutics in Inflammatory Bowel Disease IBD

The collaboration agreement grants Takeda an exclusive worldwide license to FIN524 a synthetic microbiome therapy for IBD and rights to followon products in IBD Finch Therapeutics a privately held microbiome engineering company a...